BR0108930A - Método de fornecimento de um agente ativo a um tipo celular de interesse, composição farmacêutica, pró-droga ativada por caspase, kit, método de tratamento de mamìferos, uso de um conjugado de caspase e uso de um pró-agente - Google Patents
Método de fornecimento de um agente ativo a um tipo celular de interesse, composição farmacêutica, pró-droga ativada por caspase, kit, método de tratamento de mamìferos, uso de um conjugado de caspase e uso de um pró-agenteInfo
- Publication number
- BR0108930A BR0108930A BR0108930-7A BR0108930A BR0108930A BR 0108930 A BR0108930 A BR 0108930A BR 0108930 A BR0108930 A BR 0108930A BR 0108930 A BR0108930 A BR 0108930A
- Authority
- BR
- Brazil
- Prior art keywords
- caspase
- agent
- pro
- interest
- conjugate
- Prior art date
Links
- 102000011727 Caspases Human genes 0.000 title abstract 8
- 108010076667 Caspases Proteins 0.000 title abstract 8
- 238000000034 method Methods 0.000 title abstract 6
- 239000003795 chemical substances by application Substances 0.000 title abstract 4
- 229940002612 prodrug Drugs 0.000 title abstract 4
- 239000000651 prodrug Substances 0.000 title abstract 4
- 239000013543 active substance Substances 0.000 title abstract 3
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 3
- 241000124008 Mammalia Species 0.000 title 1
- 230000001413 cellular effect Effects 0.000 abstract 1
- 229940079593 drug Drugs 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 239000008177 pharmaceutical agent Substances 0.000 abstract 1
- 230000008685 targeting Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6891—Pre-targeting systems involving an antibody for targeting specific cells
- A61K47/6899—Antibody-Directed Enzyme Prodrug Therapy [ADEPT]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Nanotechnology (AREA)
- Biophysics (AREA)
- Epidemiology (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Crystallography & Structural Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oncology (AREA)
- General Chemical & Material Sciences (AREA)
- Medical Informatics (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
"MéTODO DE FORNECIMENTO DE UM AGENTE ATIVO A UM TIPO CELULAR DE INTERESSE, COMPOSIçãO FARMACêUTICA, PRó-DROGA ATIVADA POR CASPASE, KIT, MéTODO DE TRATAMENTO DE MAMìFEROS, USO DE UM CONJUGADO DE CASPASE E USO DE UM PRó-AGENTE". A presente invenção proporciona métodos inovadores para o fornecimento localizado de agentes farmacêuticos através da administração de um conjugado de caspase que se dirige a um tipo celular de interesse e da administração adicional de um pró-agente que é convertido localmente, na presença da caspase, em um agente ativo. A presente invenção proporciona, ainda, agentes direcionadores inovadores que compreendem uma caspase, bem como pró-drogas inovadoras que compreendem uma porção de pró-droga clivável por caspase. A presente invenção também fornece composições farmacêuticas, bem como métodos de tratamento que compreendem os conjugados de caspase e pró-drogas de acordo com a presente invenção
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US18477900P | 2000-02-24 | 2000-02-24 | |
PCT/US2001/005709 WO2001062300A2 (en) | 2000-02-24 | 2001-02-22 | Caspase activated prodrugs therapy |
Publications (1)
Publication Number | Publication Date |
---|---|
BR0108930A true BR0108930A (pt) | 2002-12-10 |
Family
ID=22678303
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR0108930-7A BR0108930A (pt) | 2000-02-24 | 2001-02-22 | Método de fornecimento de um agente ativo a um tipo celular de interesse, composição farmacêutica, pró-droga ativada por caspase, kit, método de tratamento de mamìferos, uso de um conjugado de caspase e uso de um pró-agente |
Country Status (15)
Country | Link |
---|---|
US (1) | US20070104719A1 (pt) |
EP (1) | EP1257296A2 (pt) |
JP (1) | JP2003523407A (pt) |
KR (1) | KR20020082227A (pt) |
CN (1) | CN1406137A (pt) |
AU (1) | AU783679B2 (pt) |
BR (1) | BR0108930A (pt) |
CA (1) | CA2399255A1 (pt) |
HU (1) | HUP0300024A2 (pt) |
IL (1) | IL150992A0 (pt) |
MX (1) | MXPA02007939A (pt) |
NZ (1) | NZ520458A (pt) |
PL (1) | PL358187A1 (pt) |
WO (1) | WO2001062300A2 (pt) |
ZA (1) | ZA200206105B (pt) |
Families Citing this family (37)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7097840B2 (en) * | 2000-03-16 | 2006-08-29 | Genentech, Inc. | Methods of treatment using anti-ErbB antibody-maytansinoid conjugates |
US7468354B2 (en) | 2000-12-01 | 2008-12-23 | Genspera, Inc. | Tissue specific prodrugs |
US7125839B2 (en) | 2002-02-07 | 2006-10-24 | Massachusetts Institute Of Technology | Anti-pathogen treatments |
US8088387B2 (en) | 2003-10-10 | 2012-01-03 | Immunogen Inc. | Method of targeting specific cell populations using cell-binding agent maytansinoid conjugates linked via a non-cleavable linker, said conjugates, and methods of making said conjugates |
WO2004111192A2 (en) | 2003-05-29 | 2004-12-23 | The Scripps Research Institute | Targeted delivery to legumain-expressing cells |
CA2679643A1 (en) * | 2007-03-09 | 2008-09-18 | The University Of British Columbia | Procaspase 8-mediated disease targeting |
US9029508B2 (en) | 2008-04-29 | 2015-05-12 | Abbvie Inc. | Dual variable domain immunoglobulins and uses thereof |
WO2009141826A2 (en) | 2008-05-22 | 2009-11-26 | Ramot At Tel Aviv University Ltd. | Novel conjugates of polymers having a therapeutically active agent and an angiogenesis targeting moiety attached thereto and uses thereof in the treatment of angiogenesis related diseases |
EP2303288A4 (en) | 2008-05-22 | 2015-04-22 | Univ Ramot | CONJUGATES OF A POLYMER, BISPHOSPHONATE AND ANTI-ANGIOGENESIS AGENT AND USES THEREOF IN THE TREATMENT AND MONITORING OF DISEASES RELATING TO BONES |
EP2300021A4 (en) * | 2008-05-22 | 2014-10-08 | Univ Ramot | CONJUGATE OF A POLYMER, ANTI-ANGIOGENESE AGENT AND TARGETING REST, AND USES THEREOF FOR THE TREATMENT OF BONE-RELATED ANGIOGENESIS STATES |
BRPI0913406A2 (pt) | 2008-06-03 | 2018-01-09 | Abbott Lab | imunoglobulinas de domínio variável duplo e usos das mesmas |
KR20110016959A (ko) | 2008-06-03 | 2011-02-18 | 아보트 러보러터리즈 | 이원 가변 도메인 면역글로불린 및 이의 용도 |
MX2010014574A (es) | 2008-07-08 | 2011-04-27 | Abbott Lab | Inmunoglobulinas de dominio variable dual para prostaglandina e2 y usos de las mismas. |
RU2012112550A (ru) | 2009-09-01 | 2013-10-10 | Эбботт Лэборетриз | Иммуноглобулины с двумя вариабельными доменами и их применение |
US20110076709A1 (en) * | 2009-09-28 | 2011-03-31 | Quest Diagnostics Investments Incorporated | Method for the Diagnosis of Leukemia Using Caspase-3 |
BR112012008833A2 (pt) | 2009-10-15 | 2015-09-08 | Abbott Lab | imunoglobulinas de dominio variavel duplo e usos das mesmas |
UY32979A (es) | 2009-10-28 | 2011-02-28 | Abbott Lab | Inmunoglobulinas con dominio variable dual y usos de las mismas |
JP2013537415A (ja) | 2010-08-03 | 2013-10-03 | アッヴィ・インコーポレイテッド | 二重可変ドメイン免疫グロブリンおよびその使用 |
JP2013539364A (ja) | 2010-08-26 | 2013-10-24 | アッヴィ・インコーポレイテッド | 二重可変ドメイン免疫グロブリンおよびその使用 |
SG189942A1 (en) * | 2010-12-29 | 2013-06-28 | Arrowhead Res Corp | In vivo polynucleotide delivery conjugates having enzyme sensitive linkages |
KR20130110218A (ko) | 2011-03-02 | 2013-10-08 | 한국과학기술연구원 | 방사선 또는 자외선 조사에 의해 활성화되는 항암제 전구체 및 이의 용도 |
CN104159920A (zh) | 2011-12-30 | 2014-11-19 | 艾伯维公司 | 针对il-13和/或il-17的双重可变结构域免疫球蛋白 |
US9687562B2 (en) | 2012-03-05 | 2017-06-27 | Ramot At Tel-Aviv University Ltd. | Polymers having therapeutically active agents conjugated thereto, processes of preparing same and uses thereof |
JP6109952B2 (ja) | 2012-11-01 | 2017-04-05 | アッヴィ・インコーポレイテッド | 抗vegf/dll4二重可変ドメイン免疫グロブリンおよびこれらの使用 |
JP2016522793A (ja) | 2013-03-15 | 2016-08-04 | アッヴィ・インコーポレイテッド | IL−1βおよび/またはIL−17に対して指向された二重特異的結合タンパク質 |
ES2857192T3 (es) * | 2014-06-03 | 2021-09-28 | Jiaray Pharmaceuticals Inc | Conjugado de mitomicina |
US10125105B2 (en) | 2014-06-11 | 2018-11-13 | Arizona Board Of Regents On Behalf Of The University Of Arizona | Triazabutadienes as cleavable cross-linkers |
US9593080B1 (en) | 2014-06-11 | 2017-03-14 | The Arizona Board Of Regents On Behalf Of The University Of Arizona | Triazabutadienes as cleavable cross-linkers |
US10047061B2 (en) | 2014-06-11 | 2018-08-14 | Arizona Board Of Regents On Behalf Of The University Of Arizona | Water-soluble triazabutadienes |
US9775914B2 (en) * | 2014-11-20 | 2017-10-03 | Pharosgen Co., Ltd. | Prodrugs activated by caspase |
US10093733B2 (en) | 2014-12-11 | 2018-10-09 | Abbvie Inc. | LRP-8 binding dual variable domain immunoglobulin proteins |
TW201710286A (zh) | 2015-06-15 | 2017-03-16 | 艾伯維有限公司 | 抗vegf、pdgf及/或其受體之結合蛋白 |
US10954195B2 (en) | 2015-08-11 | 2021-03-23 | Arizona Board Of Regents On Behalf Of The University Of Arizona | Substituted triazenes protected from degradation by carboxylation of N1 |
CA3022751A1 (en) * | 2016-05-04 | 2017-11-09 | Navigo Proteins Gmbh | Targeted compounds for the site-specific coupling of chemical moieties comprising a peptide linker |
US11339129B2 (en) | 2016-07-29 | 2022-05-24 | Arizona Board of Regents on behalf of the University of Arizon | Triazabutadienes as cleavable cross-linkers |
JP7404252B2 (ja) * | 2017-11-08 | 2023-12-25 | ヤフェイ シャンハイ バイオロジー メディスン サイエンス アンド テクノロジー カンパニー リミテッド | 生体分子のコンジュゲートおよびその使用 |
CN114728073A (zh) * | 2019-09-19 | 2022-07-08 | 思进股份有限公司 | 药物从生物活性化合物的内化缀合物的选择性释放 |
Family Cites Families (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4675187A (en) * | 1983-05-16 | 1987-06-23 | Bristol-Myers Company | BBM-1675, a new antibiotic complex |
US4975278A (en) * | 1988-02-26 | 1990-12-04 | Bristol-Myers Company | Antibody-enzyme conjugates in combination with prodrugs for the delivery of cytotoxic agents to tumor cells |
DE3920358A1 (de) * | 1989-06-22 | 1991-01-17 | Behringwerke Ag | Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung |
IL101943A0 (en) * | 1991-05-24 | 1992-12-30 | Genentech Inc | Structure,production and use of heregulin |
US5288931A (en) * | 1991-12-06 | 1994-02-22 | Genentech, Inc. | Method for refolding insoluble, misfolded insulin-like growth factor-I into an active conformation |
WO1999006072A1 (en) * | 1997-07-30 | 1999-02-11 | Boehringer Mannheim Corporation | Cyclized prodrugs |
EP1037911A4 (en) * | 1997-12-10 | 2003-07-23 | Univ Washington | ANTI-PATHOGEN SYSTEM AND METHOD FOR USE THEREOF |
US6379950B1 (en) * | 1998-01-09 | 2002-04-30 | Thomas Jefferson University | Recombinant, active caspases and uses thereof |
US6645490B2 (en) * | 1998-03-02 | 2003-11-11 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Chimeric proteins with cell-targeting specificity and apoptosis-inducing activities |
US6833373B1 (en) * | 1998-12-23 | 2004-12-21 | G.D. Searle & Co. | Method of using an integrin antagonist and one or more antineoplastic agents as a combination therapy in the treatment of neoplasia |
GB2360771A (en) * | 2000-03-28 | 2001-10-03 | Antisoma Res Ltd | Compounds for targeting |
EP1286700A2 (en) * | 2000-06-01 | 2003-03-05 | Universite Catholique De Louvain | Tumor activated prodrug compounds |
-
2001
- 2001-02-22 KR KR1020027011059A patent/KR20020082227A/ko not_active Application Discontinuation
- 2001-02-22 HU HU0300024A patent/HUP0300024A2/hu unknown
- 2001-02-22 MX MXPA02007939A patent/MXPA02007939A/es not_active Application Discontinuation
- 2001-02-22 CA CA002399255A patent/CA2399255A1/en not_active Abandoned
- 2001-02-22 NZ NZ520458A patent/NZ520458A/en not_active IP Right Cessation
- 2001-02-22 PL PL01358187A patent/PL358187A1/xx not_active Application Discontinuation
- 2001-02-22 BR BR0108930-7A patent/BR0108930A/pt not_active IP Right Cessation
- 2001-02-22 WO PCT/US2001/005709 patent/WO2001062300A2/en active IP Right Grant
- 2001-02-22 JP JP2001561363A patent/JP2003523407A/ja active Pending
- 2001-02-22 CN CN01805618A patent/CN1406137A/zh active Pending
- 2001-02-22 EP EP01912935A patent/EP1257296A2/en not_active Withdrawn
- 2001-02-22 AU AU41667/01A patent/AU783679B2/en not_active Ceased
- 2001-02-22 IL IL15099201A patent/IL150992A0/xx unknown
-
2002
- 2002-07-31 ZA ZA200206105A patent/ZA200206105B/xx unknown
-
2006
- 2006-09-29 US US11/537,578 patent/US20070104719A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
WO2001062300A3 (en) | 2002-04-25 |
CN1406137A (zh) | 2003-03-26 |
AU4166701A (en) | 2001-09-03 |
CA2399255A1 (en) | 2001-08-30 |
PL358187A1 (en) | 2004-08-09 |
NZ520458A (en) | 2005-02-25 |
WO2001062300A2 (en) | 2001-08-30 |
KR20020082227A (ko) | 2002-10-30 |
US20070104719A1 (en) | 2007-05-10 |
EP1257296A2 (en) | 2002-11-20 |
IL150992A0 (en) | 2003-02-12 |
HUP0300024A2 (en) | 2003-05-28 |
MXPA02007939A (es) | 2003-02-10 |
AU783679B2 (en) | 2005-11-24 |
ZA200206105B (en) | 2003-07-31 |
JP2003523407A (ja) | 2003-08-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR0108930A (pt) | Método de fornecimento de um agente ativo a um tipo celular de interesse, composição farmacêutica, pró-droga ativada por caspase, kit, método de tratamento de mamìferos, uso de um conjugado de caspase e uso de um pró-agente | |
UA91512C2 (ru) | Коньюгати олигомеров инсулина, их композиция (варианты) и применение | |
BR0316050A (pt) | Métodos de tratar, controlar ou prevenir um câncer especìfico e doença associada com angiogênese indesejada e de reduzir ou evitar um efeito adverso associado com a administração de um segundo ingrediente ativo e com terapia de radiação, terapia hormonal, terapia biológica, ou imunoterapia em um paciente sofrendo de um câncer especìfico, composição farmacêutica e kit | |
BR0115109A (pt) | Agentes terapêuticos e métodos de uso dos mesmos para a modulação da angiogênese | |
BR0008590A (pt) | Agente de entrega polimérico, composição, formade unidade de dosagem, método para administrarum agente biologicamente ativo a um animalnecessitando o agente, método para preparar umacomposição; e composto | |
SG156624A1 (en) | Organo-gel formulations for therapeutic applications | |
BR0108173A (pt) | Composições farmacêuticas de toxina de botulina | |
PT1146861E (pt) | Formulacoes de particulas de hidrogel | |
BR9815442A (pt) | Liberação terapêutica dirigida de compostos de vitamina d | |
ES2109899T1 (es) | Metodo, composiciones y kits para aumentar la biodisponibilidad oral de agentes farmaceuticos. | |
EE200200578A (et) | Antihüpertensiivsete ja antiangiogeensete ainete terapeutilised kombinatsioonid | |
DE60326887D1 (de) | Pharmazeutische zusammensetzungen enthaltend botulinumtoxin und humanes serum-albumin | |
BR0109672A (pt) | Uso de zd6126 ou de um seu sal farmaceuticamente aceitável e um de: um agente antitumoral de plantina e um taxano, composição farmacêutica, produto de combinação, kit, e, método para a produção de um efeito de danificação vascular em um animal de sangue quente | |
ATE337019T1 (de) | Geladene lipide und deren verwendung | |
BR0209658A (pt) | Derivados de 4-amino-5-fenil-7-1ciclobutil-pirrolo [2,3-d] pirimidina | |
BR9909915A (pt) | Composições adjuvantes | |
AR024516A1 (es) | Compuestos bi-aromaticos analogos de la vitamina d, su utilizacion, composicion farmaceutica y composicion cosmetica que comprenden al menos uno de dichos compuestos y utilizacion de dicha composicion cosmetica. | |
FI914391A0 (fi) | Sammansaettningar vilka foerstaerker hudens permeabilitet. | |
BR0109266A (pt) | Composto, composição farmacêutica, método de tratamento de um mamìfero afetado com um câncer, método de liberação de um composto nas células de um mamìfero afetado com um câncer e uso do composto | |
BR0012082A (pt) | Formulação farmacêutica para administração compreendendo morfina e seu uso | |
BR9914419A (pt) | Terapia para melhoria da percepção | |
WO2002087465A3 (en) | Compositions and methods of double-targeting virus infections and cancer cells | |
BRPI0008228B8 (pt) | composição farmacêutica contendo n-benzoil estaurosporina e agentes solubilizantes | |
WO2001034614A3 (en) | Compositions and methods for double-targeting virus infections and targeting cancer cells | |
DK1280558T3 (da) | Halvfast indgivelsesvehikel og farmaceutiske sammensætninger |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 9A,10A E 11A ANUIDADE(S). |
|
B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2144 DE 07/02/2012. |
|
B15K | Others concerning applications: alteration of classification |
Ipc: C07K 16/32 (2006.01), A61K 47/68 (2017.01), B82Y 5 |